Study of Psilocybin for Anorexia in Young Adults (SPANYA)
Single-group interventional Phase II study (n=40) of psilocybin therapy for refractory Anorexia Nervosa in young adults with two dosing sessions (20 mg then up to 30 mg) plus preparatory and integration therapy.
Details
Single-site, single-group Phase II study evaluating psilocybin therapy for refractory Anorexia Nervosa in young adults (18–25 years).
Intervention includes three preparatory therapy sessions, two psilocybin dosing sessions (first 20 mg, second up to 30 mg) and a total of six integration sessions; selected family members co-enrol and attend portions of sessions for psychoeducation and support.
Outcomes assess eating-disorder symptoms pre- and post-treatment and test the hypothesis that increases in cognitive flexibility predict long-term reductions in cognitive rigidity, habitual eating, and exercise behaviours.